SCHEMBL4745849

SCHEMBL4745849

Cc1ccc2c(c1)c(-c1cc3ccccc3c3ccccc13)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.35
CCR8 P51685 2/20 0.35
ALDH1A1 P00352 5/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
MAPK1 P28482 2/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
HIF1A Q16665 1/20 0.34
CYP11B1 P15538 1/20 0.33
TOP2A P11388 1/20 0.33
CYP1A2 P05177 2/20 0.32
CCR5 P51681 1/20 0.32
HPRT1 P00492 1/20 0.31
BCHE P06276 1/20 0.31
ADORA3 P0DMS8 2/20 0.31
MAPT P10636 2/20 0.31
MAOA P21397 1/20 0.31
LCK P06239 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745945 0.96 HPRT1 (0.37) CCR1CCR8ALDH1A1L3MBTL1MAPK1
SCHEMBL4745860 0.92 MAOA (0.35) CCR1CCR8ALDH1A1HPGDHSD17B10
SCHEMBL4746409 0.92 PDK2 (0.33) CCR1CCR8ALDH1A1L3MBTL1MAPK1
SCHEMBL4746466 0.91 TOP2A (0.32) CCR1CCR8ALDH1A1MAPK1TOP2A
SCHEMBL4746394 0.91 MEN1 (0.32) CCR1CCR8ALDH1A1MAPK1TOP2A
SCHEMBL4746272 0.90 MAPT (0.32) CCR1CCR8MAPK1TOP2ABCHE
SCHEMBL4746461 0.90 TOP2A (0.33) CCR1CCR8ALDH1A1MAPK1TOP2A
SCHEMBL4745985 0.90 BCHE (0.33) ALDH1A1TOP2ABCHE
SCHEMBL4745959 0.89 CYP1A2 (0.35) CCR1CCR8ALDH1A1L3MBTL1MAPK1
SCHEMBL4746180 0.89 TOP2A (0.37) CCR1CCR8ALDH1A1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 CCR1 3197/4885CCR8 3139/4885ALDH1A1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.